22 maj: Resultat af auktion over 0,25 pct. Danske Stat 2022 og 0,50 pct. ..
22 maj: Atlantic Petroleum P/F - Suspenderet
22-05-2019 10:38:36

Lundbeck increases its share capital by 26,098 shares (0.0131 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 22 May 2019 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 130,490 as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 26,098 shares at DKK 113. Proceeds to the company are DKK 2,949,074 (approximately USD 0.446 million). The increase corresponds to approximately 0.0131 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority.

Lundbeck's current share capital amounts to DKK 995,553,135. The capital increase is expected to be finalized shortly, and the total number of voting rights and the total share capital will after this capital increase be:

 

Number of shares (nominal value DKK 5) Nominal value of shares

(DKK)

    Number of votes 
199,136,725 995,683,625 199,136,725

Lundbeck contacts

Investors:

Palle Holm Olesen

Vice President, Investor Relations

PALO@lundbeck.com

+45 30 83 24 26

Media:

Mads Kronborg

Senior Director, Corporate Communication

MAVK@lundbeck.com

+45 36 43 40 00 

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Attachment

logo.jpg

Relateret indhold
29 maj - 
Onsdagens aktier: Genmab fik klø i uroligt marked
29 maj - 
Aktier/middag: Genmab og Ambu går til bunds i rødt mark..
29 maj - 
Aktier/åbning: Genmab sendes til bunds i C25 med lutter..
Relateret debat
09 maj - 
Så er vi ved at være ved opsamling omkring 268-270 opti..
08 maj - 
Nogen tjener man på, andre taber man lidt, har tjent 8,..
08 maj - 
Du går godt nok hurtigt ud af dine handler. Du må da ta..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Lars Christensens Verden - Episode 21: Hvis virksomhedernes betalingsevne svigter, knækker aktiemarkedet

14-06-2019 06:00:00
I episode 21 af podcastserien “Lars Christensens Verden” stilles der skarpt på asset allokering.Euroinvestors chefredaktør Lars Christensen har adm. direktør i og stifter af Copenhagen Allocation Partner (CAP) Morten Kongshaug med i studiet til en samtale om, hvilke værktøjer og indikatorer Morten Kongshaug benytter til at vurdere, om man skal være over- eller undervægt aktier i sin portefølje, og..

Fredagens aktier: Carlsberg sendt til bunds i overvejende rødt C25

14-06-2019 17:02:57
På en dag uden de helt store selskabsnyheder blev Carlsberg fredag sendt til bunds i et rødt C25-indeks, der samlet dykkede 0,7 pct. til 1125,94.Bryggeriaktien faldt 2,9 pct. til 880 kr., hvilket ifølge Martin Munk, senioraktierådgiver i Jyske Bank, kan skyldes, at salgstal fra et analysehus viste svaghed i Vesteuropa - særligt i Storbritannien og Italien.- Der er kommet nye salgstal fra Nielsen (..

Ørsted: Fransk konkurrent vinder havvindudbud i Frankrig

Relaterede nyheder
14-06-2019 12:29:09
Den statsejede franske energikoncern EDF er fredag blevet udråbt til vinderen af en udbudsrunde for havvind i Frankrig.Det oplyser den franske miljøminister, François de Rugy, fredag ifølge nyhedsbureauet Reuters.- EDF er blevet valgt, udtaler han ifølge nyhedsbureauet fredag.Dermed har det franske selskab, der har tyske Innogy og Enbridge som partnere, vundet retten til at opføre en havvindmøllep..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Lundbeck A/S 253,90 -1,6% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. juni 2019 22:38:37
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB4 - 2019-06-15 22:38:37 - 2019-06-15 22:38:37 - 1 - Website: OKAY